Floriane Michel1,2, Fabiana Cancrini3,4, Géraldine Cancel-Tassin3, Xavier Gamé5, Eric Huyghe5, Aurélien Rock6, Grégoire Léon7, Audrey Uzan8, François-Régis Desfemmes9, Benoît Peyronnet10, Jérémy Fallot11, Priscilla Léon12, Emmanuel Rolland13, Marie-Aimée Perrouin-Verbe14, Jacques Wodey15, Grégoire Capon16, Gilles Karsenty17, Morgan Rouprêt3,18, Olivier Cussenot3,8, Hussa Alshehhi19, Eva Comperat3,19, Véronique Phé3,8. 1. Department of Urology and Kidney Transplantation, Aix-Marseille University, La Conception Hospital, Assistance Publique-Hôpitaux de Marseille, 147 Boulevard Baille, 13005, Marseille, France. floriane.michel@ap-hm.fr. 2. Sorbonne University, GRC5 Predictive Onco-urology, Assistance Publique-Hôpitaux de Paris, Paris, France. floriane.michel@ap-hm.fr. 3. Sorbonne University, GRC5 Predictive Onco-urology, Assistance Publique-Hôpitaux de Paris, Paris, France. 4. Department of Medical and Surgical Sciences and Translational Medicine, Sapienza University of Rome, Sant'Andrea University Hospital, Rome, Italy. 5. Department of Urology, CHU Rangueil, Université Paul Sabatier Toulouse III, Toulouse, France. 6. Department of Urology, Groupe Hospitalier de L'Institut Catholique Lillois, Lille, France. 7. Department of Urology and Transplantation, CHU de Caen, Caen, France. 8. Department of Urology, Sorbonne University, Tenon Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France. 9. Department of Urology, Hôpital d'instruction Des Armées du Val de Grace, Paris, France. 10. Department of Urology, University of Rennes, Rennes, France. 11. Department of Urology, Royal Prince Alfred Hospital, Sydney, NSW, Australia. 12. Department of Urology, Clinique Urologie Royan, Royan, France. 13. Department of Urology, Clinique Toulouse Lautrec, Albi, France. 14. Department of Urology and Transplantation Surgery, Nantes University Hospital, Nantes, France. 15. Department of Urology, Clinique Rhône Durance, Avignon, France. 16. Department of Urology, University of Bordeaux, Bordeaux, France. 17. Department of Urology and Kidney Transplantation, Aix-Marseille University, La Conception Hospital, Assistance Publique-Hôpitaux de Marseille, 147 Boulevard Baille, 13005, Marseille, France. 18. Department of Urology, Sorbonne University, Pitié-Salpêtrière Academic Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France. 19. Department of Pathology, Sorbonne University, Tenon Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Abstract
PURPOSE: To establish whether the expression of markers of cell differentiation (CK7, CK14, CK20, GATA3), apoptosis (p53), proliferation (Ki67, STAG2) and peri-tumoural lymphocytes (CD3, CD8), provides specific information about urothelial carcinogenesis in neuro-urological patients with bladder cancer (NBC). METHODS: Tissue samples from NBC were retrieved from 15 centres in France and compared to control samples from non neuro-urological patients with bladder cancer (NNBC) and from neuro-urological patients without bladder cancer (NB). The expression of CK7, CK14, CK20, GATA3, p53, Ki67, STAG2, CD3 and CD8 markers was analysed using immunohistochemistry of tissue microarray sections. RESULTS: Overall, tissue samples from 124 patients were included in the study (n = 72 NBC, n = 26 NNBC and n = 26 NB). Muscle invasive bladder cancer (MIBC) was found in 52 NBC patients (72.2%) and squamous cell differentiation in 9 (12.5%). In NBC samples, the expression of CK20 and GATA3 was significantly more frequent in NMIBC compared to MIBC (p = 0.015 and p = 0.004, respectively). CK20 and GATA3 were significantly more expressed in NBC compared to NNBC (p < 0.001 and p = 0.010, respectively). The expression of CK14, Ki67, CD3 and CD8 was significantly more frequent in NBC than in NNBC samples (p = 0.005, p < 0.001, p < 0.001 and p < 0.001, respectively). The expression of CD3 and CD8 was similar in NBC and NB samples. CONCLUSION: In NBC, markers of basal differentiation, proliferation and peri-tumoural lymphocytes were significantly more expressed compared to NNBC controls. These results suggest the aggressiveness of NBC and the role of chronic inflammation in the carcinogenesis of bladder cancer in neuro-urological patients.
PURPOSE: To establish whether the expression of markers of cell differentiation (CK7, CK14, CK20, GATA3), apoptosis (p53), proliferation (Ki67, STAG2) and peri-tumoural lymphocytes (CD3, CD8), provides specific information about urothelial carcinogenesis in neuro-urological patients with bladder cancer (NBC). METHODS: Tissue samples from NBC were retrieved from 15 centres in France and compared to control samples from non neuro-urological patients with bladder cancer (NNBC) and from neuro-urological patients without bladder cancer (NB). The expression of CK7, CK14, CK20, GATA3, p53, Ki67, STAG2, CD3 and CD8 markers was analysed using immunohistochemistry of tissue microarray sections. RESULTS: Overall, tissue samples from 124 patients were included in the study (n = 72 NBC, n = 26 NNBC and n = 26 NB). Muscle invasive bladder cancer (MIBC) was found in 52 NBC patients (72.2%) and squamous cell differentiation in 9 (12.5%). In NBC samples, the expression of CK20 and GATA3 was significantly more frequent in NMIBC compared to MIBC (p = 0.015 and p = 0.004, respectively). CK20 and GATA3 were significantly more expressed in NBC compared to NNBC (p < 0.001 and p = 0.010, respectively). The expression of CK14, Ki67, CD3 and CD8 was significantly more frequent in NBC than in NNBC samples (p = 0.005, p < 0.001, p < 0.001 and p < 0.001, respectively). The expression of CD3 and CD8 was similar in NBC and NB samples. CONCLUSION: In NBC, markers of basal differentiation, proliferation and peri-tumoural lymphocytes were significantly more expressed compared to NNBC controls. These results suggest the aggressiveness of NBC and the role of chronic inflammation in the carcinogenesis of bladder cancer in neuro-urological patients.
Authors: Marcus George Kwesi Cumberbatch; Ibrahim Jubber; Peter C Black; Francesco Esperto; Jonine D Figueroa; Ashish M Kamat; Lambertus Kiemeney; Yair Lotan; Karl Pang; Debra T Silverman; Ariana Znaor; James W F Catto Journal: Eur Urol Date: 2018-09-26 Impact factor: 20.096
Authors: Woonyoung Choi; Sima Porten; Seungchan Kim; Daniel Willis; Elizabeth R Plimack; Jean Hoffman-Censits; Beat Roth; Tiewei Cheng; Mai Tran; I-Ling Lee; Jonathan Melquist; Jolanta Bondaruk; Tadeusz Majewski; Shizhen Zhang; Shanna Pretzsch; Keith Baggerly; Arlene Siefker-Radtke; Bogdan Czerniak; Colin P N Dinney; David J McConkey Journal: Cancer Cell Date: 2014-02-10 Impact factor: 31.743
Authors: Erik Veskimäe; Estefania Linares Espinos; Harman Maxim Bruins; Yuhong Yuan; Richard Sylvester; Ashish M Kamat; Sharokh F Shariat; J Alfred Witjes; Eva M Compérat Journal: Eur Urol Oncol Date: 2019-10-08